Pharmos reports Phase II data

Pharmos (PARS; EASD:PHRM) said data from a 101-patient study showed dexanabinol (HU-211) reduced the mean time in which intracranial pressure (ICP) exceeded 25 mmHg by 60-80 percent in the first 4 day...